Maze Therapeutics (MAZE) Revenue (2024 - 2026)

Maze Therapeutics (MAZE) posted Revenue of $20.0 million for Q1 2026, up 113.11% sequentially from -$152.5 million in Q4 2024.

Analysis

Maze Therapeutics (MAZE) Revenue (2024 - 2026) Analysis & Trends

Maze Therapeutics has reported Revenue for 2 years, with the latest figure at $20.0 million in Q1 2026.

Quarterly Revenue changed N/A year-over-year to $20.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.0 million (up 114.81% YoY) and the FY2024 annual result came in at $15.0 million, changed N/A from the prior year.
Revenue improved to $20.0 million in Q1 2026 per MAZE's latest filing, from -$152.5 million in the prior quarter.
Over five years, Revenue peaked at $20.0 million in Q1 2026 and troughed at -$152.5 million in Q4 2024.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	1.52 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	145.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	1.71 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	1.29 Bn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	674.14 Mn
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	425.49 Mn
10	Maze Therapeutics	1.55 Bn	1.55 Bn	-	-

Historic Data

Download Data